Research progress on the intrinsic non-immune function of PD-L1 in tumors (Review)

Programmed death ligand 1 (PD-L1) is widely expressed in human tumors. It is widely known for its immunosuppressive function as it can help tumor cells evade T cell immune killing through the PD-1/PD-L1 signal. A number of clinical trials have proved that the destruction of the combination of PD-1 and PD-L1 by antibodies could significantly affect patients with advanced cancer. However, a number of patients with cancer still cannot benefit from PD-1/PD-L1 blocking therapy. The main reason is that PD-L1 also has some intrinsic regulatory functions to promote the progression of tumors. PD-L1 Protein contains an intrinsic domain that could link to other signal pathways, but the mechanism has not yet been fully revealed. The present review mainly discussed the non-immune checkpoint functions of PD-L1, such as its role in regulating cell proliferation, cell metabolism, drug resistance and maintaining epithelial-mesenchymal transition and stemness.

[1]  Amit B. Kasar,et al.  Programmed Death-Ligand 1 (PD-L1) Positivity and Factors Associated with Poor Prognosis in Patients with Gastric Cancer: An Umbrella Meta-Analysis , 2022, Cureus.

[2]  S. Ramkissoon,et al.  Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression. , 2021 .

[3]  B. Baradaran,et al.  PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  Xiang Yu,et al.  HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis , 2021, Digestive Diseases and Sciences.

[5]  Yang Zhang,et al.  KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway , 2020, Cell Death & Differentiation.

[6]  H. Tomita,et al.  PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. , 2020, Gastroenterology.

[7]  Yun Wang,et al.  Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis , 2020, International Journal of Colorectal Disease.

[8]  J. Tainer,et al.  PD-L1-Mediated Gasdermin C Expression Switches Apoptosis to Pyroptosis in Cancer Cells and Facilitates Tumor Necrosis , 2020, Nature Cell Biology.

[9]  S. Mousa,et al.  NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer , 2020, Cells.

[10]  Aleksandra A. Kolodziejczyk,et al.  Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy , 2020, Nature Cell Biology.

[11]  Yaming Li,et al.  PD-L1 in Lung Adenocarcinoma: Insights into the Role of 18F-FDG PET/CT , 2020, Cancer management and research.

[12]  Dong Li,et al.  Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells , 2020, Oncology research.

[13]  Liewei Wang,et al.  Regulation of sister chromatid cohesion by nuclear PD-L1 , 2020, Cell Research.

[14]  Zheyan Liu,et al.  A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients , 2020, Cancer Cell International.

[15]  Hong Wang,et al.  Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells , 2020, Journal of Experimental & Clinical Cancer Research.

[16]  B. O'Malley,et al.  PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma , 2019, British Journal of Cancer.

[17]  Juan Zhang,et al.  PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling , 2019, Bioscience reports.

[18]  Sidong Huang,et al.  CD44 promotes PD-L1 expression and its tumor-intrinsic function in breast and lung cancers. , 2019, Cancer research.

[19]  M. Hung,et al.  Mechanisms Controlling PD-L1 Expression in Cancer. , 2019, Molecular cell.

[20]  Yonghong Sun,et al.  Phosphorylation of HSF1 by PIM2 induces PD-L1 expression and promotes tumor growth in breast cancer. , 2019, Cancer research.

[21]  Y. Liu,et al.  LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint , 2019, Cell Death & Disease.

[22]  Guang-Yu Lian,et al.  LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. , 2019, Life sciences.

[23]  Yang Zhang,et al.  The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer , 2019, Respiratory Research.

[24]  Meng Yang,et al.  miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death‐ligand 1 immune checkpoint , 2019, Experimental cell research.

[25]  Hu Li,et al.  PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy. , 2019, Molecular cell.

[26]  Ping Yang,et al.  PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways. , 2019, Cancer letters.

[27]  Rujun Xue,et al.  Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis , 2019, OncoTargets and therapy.

[28]  Xin Hu,et al.  Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer. , 2019, Cancer research.

[29]  Tao Xi,et al.  MiR-873/PD-L1 axis regulates the stemness of breast cancer cells , 2019, EBioMedicine.

[30]  R. Bruggmann,et al.  Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A5491 , 2018, Neoplasia.

[31]  H. Baba,et al.  PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer , 2017, Annals of surgery.

[32]  Min Zhang,et al.  MiR‐940 promotes the proliferation and migration of gastric cancer cells through up‐regulation of programmed death ligand‐1 expression , 2018, Experimental cell research.

[33]  A. Tan,et al.  Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression , 2018, Molecular Cancer Research.

[34]  Q. Gao,et al.  Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression , 2018, Cancers.

[35]  Jinzhong Liu,et al.  Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD‐L1 , 2018, Cancer medicine.

[36]  T. Schumacher,et al.  Regulation and Function of the PD-L1 Checkpoint. , 2018, Immunity.

[37]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[38]  S. Baba,et al.  Metabolic characteristics of programmed cell death‐ligand 1‐expressing lung cancer on 18F‐fluorodeoxyglucose positron emission tomography/computed tomography , 2017, Cancer medicine.

[39]  Yiduo Zhang,et al.  PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. , 2017, Lung cancer.

[40]  K. Flaherty,et al.  PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression , 2017, Journal of the American Academy of Dermatology.

[41]  C. Wellbrock,et al.  PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. , 2017, Cell reports.

[42]  James L. Gulley,et al.  A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells , 2017, Oncoimmunology.

[43]  Olfat Al-Harazi,et al.  PD‐L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation , 2017, International journal of cancer.

[44]  H. Yang,et al.  Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells , 2017, Oncogene.

[45]  Haitao Ma,et al.  PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[46]  H. Mankin,et al.  Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells , 2017, Oncotarget.

[47]  Qi Zhou,et al.  Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy , 2017, Cellular Physiology and Biochemistry.

[48]  J. Lasota,et al.  Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas , 2017, Modern Pathology.

[49]  T. Curiel,et al.  Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. , 2016, Cancer research.

[50]  Young A Kim,et al.  PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. , 2016, Human pathology.

[51]  Guoqiang Chen,et al.  CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling , 2016, Journal of Hematology & Oncology.

[52]  N. Zhang,et al.  The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. , 2016, International journal of oncology.

[53]  A. Satelli,et al.  Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients , 2016, Scientific Reports.

[54]  M. Vetizou,et al.  Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. , 2016, Immunity.

[55]  C. Jiang,et al.  Regulation of PD-L1: a novel role of pro-survival signalling in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  G. Fuller,et al.  PD-L1 expression and prognostic impact in glioblastoma. , 2016, Neuro-oncology.

[57]  C. Porta,et al.  Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis , 2016, Targeted Oncology.

[58]  K. Zak,et al.  Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. , 2015, Structure.

[59]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[60]  Yuzhang Wu,et al.  B7H1 Expression and Epithelial-To-Mesenchymal Transition Phenotypes on Colorectal Cancer Stem-Like Cells , 2015, PloS one.

[61]  Qi Zhao,et al.  PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma , 2015, Medical Oncology.

[62]  Lixia Diao,et al.  Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression , 2014, Nature Communications.

[63]  Jingting Jiang,et al.  B7-H1 expression associates with tumor invasion and predicts patient's survival in human esophageal cancer. , 2014, International journal of clinical and experimental pathology.

[64]  F. Gao,et al.  Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer , 2014, Breast Cancer Research and Treatment.

[65]  M. Azuma,et al.  B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin. , 2011, Cancer research.

[66]  A. Aboussekhra,et al.  Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule , 2010, Breast Cancer Research.

[67]  J. Bluestone,et al.  Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor-induced stop signal , 2009, Nature Immunology.

[68]  David W Townsend,et al.  Positron emission tomography/computed tomography. , 2008, Seminars in nuclear medicine.

[69]  G. Zhu,et al.  B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. , 2008, Blood.

[70]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[71]  D. Y. Lin,et al.  The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors , 2008, Proceedings of the National Academy of Sciences.

[72]  J. Cheville,et al.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[73]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[74]  W. Earnshaw,et al.  Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.

[75]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.